Provided by Tiger Fintech (Singapore) Pte. Ltd.

Blueprint Medicines

89.58
-0.2600-0.29%
Post-market: 89.580.00000.00%16:23 EDT
Volume:669.70K
Turnover:59.83M
Market Cap:5.72B
PE:-83.93
High:90.84
Open:90.44
Low:88.00
Close:89.84
Loading ...

Exploring High Growth Tech Stocks In The US Market March 2025

Simply Wall St.
·
13 Mar

Have Blueprint Medicines Insiders Been Selling Stock?

Simply Wall St.
·
09 Mar

Blueprint Medicines Initiated at Sector Outperform by Scotiabank

Dow Jones
·
08 Mar

Is Blueprint Medicines (NASDAQ:BPMC) A Risky Investment?

Simply Wall St.
·
07 Mar

Blueprint Medicines: Hold Rating Amid Concerns Over Ayvakit’s Liver Function Test Elevations

TIPRANKS
·
05 Mar

Blueprint Medicines Price Target Maintained With a $125.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS) and Blueprint Medicines (BPMC)

TIPRANKS
·
03 Mar

Blueprint Medicines Highlights Leading Portfolio of Mast Cell-Targeted Therapies at 2025 AAAAI / WAO Joint Congress

PR Newswire
·
28 Feb

Blueprint Medicines Corporation (BPMC): Among the Oversold Biotech Stocks to Buy Now

Insider Monkey
·
25 Feb

RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?

Zacks
·
24 Feb

Cautious Optimism: Hold Rating Given to Blueprint Medicines Amid Financial Performance Concerns and Slower Ayvakit Growth Projections

TIPRANKS
·
17 Feb

Blueprint Medicines Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.
·
15 Feb

BPMC Q4 Earnings and Sales Miss Estimates, Shares Decline

Zacks
·
15 Feb

Blueprint Medicines Price Target Maintained With a $125.00/Share by JMP Securities

Dow Jones
·
14 Feb

Morgan Stanley Sticks to Their Hold Rating for Blueprint Medicines (BPMC)

TIPRANKS
·
14 Feb

Blueprint Medicines Corporation (NASDAQ:BPMC) Is Expected To Breakeven In The Near Future

Simply Wall St.
·
14 Feb